AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion
AUTO-LT1
Phase 2 small_molecule active
Quick answer
AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion for Potential malignancy in patients who received treatment with Autolus CAR T cell therapy. is a Phase 2 program (small_molecule) at Autolus GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Autolus GmbH
- Indication
- Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active